BETHESDA, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN), is holding a conference call today at 4:30 p.m. Eastern Time to provide investors with an update on the status of its clinical trials and research and development programs.
RegeneRx is currently sponsoring five clinical trials to evaluate thymosin beta (Tß4), the company’s multi-faceted drug candidate. The three ongoing Phase 2 studies are randomized, double-blinded, placebo-controlled dermal wound healing clinical trials, one of which is being conducted by RegeneRx’s partner and European licensee, Sigma-Tau. The two newer studies, scheduled to begin this quarter, include a Phase 2 ophthalmic wound healing trial in diabetic patients, and a Phase 1A safety trial for an intravenous (IV) route of administration of Tß4 being conducted in preparation for a Phase 2 trial in patients suffering acute myocardial infarction (heart attack).